{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Filgrastim+or+equivalent&page=2", "query": { "intervention": "Filgrastim or equivalent", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Filgrastim+or+equivalent&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T06:32:24.998Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04959175", "title": "Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 320, "start_date": "2021-09-23", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04959175" }, { "nct_id": "NCT01501487", "title": "MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TAC chemotherapy", "type": "DRUG" }, { "name": "TC chemotherapy", "type": "DRUG" }, { "name": "Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy", "type": "DRUG" }, { "name": "TCH chemotherapy", "type": "DRUG" }, { "name": "T + trastuzumab followed by CEF + trastuzumab", "type": "DRUG" }, { "name": "Dose dense AC followed by T + trastuzumab", "type": "DRUG" }, { "name": "Dose dense AC followed by T + trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "PTH followed by dose dense AC of FEC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agendia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 226, "start_date": "2011-10", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2018-06-28", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 9, "location_summary": "Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tarpon Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01501487" }, { "nct_id": "NCT00066482", "title": "Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "MESNA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 19, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-17", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066482" }, { "nct_id": "NCT02029638", "title": "BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "bone marrow transplant", "type": "BIOLOGICAL" }, { "name": "MESNA", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2014-01-07", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029638" }, { "nct_id": "NCT03860844", "title": "Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Dexamethasone or equivalent", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Liposomal daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin (nonliposomal)", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Filgrastim or equivalent", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Pegaspargase (PEG) Asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "L - Asparginase", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "L - Asparaginase (Erwinase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 67, "start_date": "2019-08-06", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860844" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" }, { "nct_id": "NCT01164475", "title": "Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Fixed Dose Plerixafor", "type": "DRUG" }, { "name": "Weight-Based Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 61, "start_date": "2010-10", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 2, "location_summary": "Duarte, California • Aurora, Colorado", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164475" }, { "nct_id": "NCT00092222", "title": "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder", "HHV-8", "Malignancy", "HIV" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Observation Only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-10-28", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092222" }, { "nct_id": "NCT01850888", "title": "MIBG for Refractory Neuroblastoma and Pheochromocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Relapsed Neuroblastoma", "Metastatic Pheochromocytoma" ], "interventions": [ { "name": "131 I-Metaiodobenzylguanidine (131I-MIBG)", "type": "DRUG" }, { "name": "Potassium iodide solution", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "hematopoietic stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 15, "start_date": "2013-12", "completion_date": "2025-10-20", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01850888" }, { "nct_id": "NCT01181271", "title": "Tandem Auto-Allo Transplant for Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse, Large B-Cell, Lymphoma", "Lymphoma, Low-Grade", "T-Cell Lymphoma", "Mantle-Cell Lymphoma", "Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Busulfan (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Etoposide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Cyclophosphamide (conditioning for AUTO transplant)", "type": "DRUG" }, { "name": "Mesna (prior to AUTO transplant)", "type": "DRUG" }, { "name": "autologous (auto) peripheral blood stem cell transplantation", "type": "OTHER" }, { "name": "Neupogen", "type": "DRUG" }, { "name": "Fludarabine (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "Busulfan (conditioning for ALLO Transplant)", "type": "DRUG" }, { "name": "non-myeloablative allogeneic (allo) transplant", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2010-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-09-26T06:32:24.998Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01181271" } ] }